Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

26 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Cholera Vaccine Articles

Low-cost cholera vacc developed by IVI

22 April 2009

Crucell to manufacture parts of Wyeth vaccine

10 March 2008

Tokyo scientists develop rice-protein cholera vaccine

18 June 2007

Many vaccines in R&D, "but hurdles remain"

27 June 2005

Chiron's oral cholera vaccine available in the UK

31 May 2004

Management buyout at Chiron's Swedish vaccines business

10 May 2004

Positive results for AVANT's cholera vacc

2 February 2004

PowderJect files in EU for cholera vaccine

18 March 2002

PowderJect sets out strategy to become leading global vaccines player

5 July 2001

Acambis and Berna in vaccine cross-licensing deal

22 March 2001

Active Biotech regains ETEC vaccine from SB

8 August 2000

Vietnam plan to boost vaccines output

20 January 2000

Switzerland: warning labels on GM drugs

2 December 1999

Vaccines Business Set For Explosive Growth, Says SB

20 May 1996

SmithKline And SBL Vaccine Agreement

6 February 1995

New Chemical Entities Round-Up For 1994

6 February 1995

BIOCINE'S VACCINE DEVELOPMENT PROGRAM

25 October 1993

Showing 1-17 of 17 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS